Two Phase III biotechs will join the Nasdaq Friday morning, with radiopharma startup RayzeBio and brain disease drug developer Neumora raising $311 million and $250 million, respectively.
RayzeBio and Neumora wooed investors during a relatively icy IPO market, which is beginning…
Click here to view original post
